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Abstract Sarcoidosis is a systemic chronic inflammatory
disease of unknown aetiology, characterised by granuloma-
tous lesions with heterogeneous clinical manifestations affect-
ing multiple organs and tissues. Although the respiratory
system is most commonly affected, the disease may also
present with bone lesions. We report the case of a 31-year-
old woman who presented with low back pain and no history
of cancer and who was found to have suspicious lesions
involving the entire spine on magnetic resonance imaging
(MRI). The patient underwent 18F-fluorodeoxyglucose
(FDG) PET/CT to search for a primary tumour and for
staging purposes. 18F-FDG PET/CT revealed a pattern of
hypermetabolic activity in widespread skeletal lesions and in
a single left cervical lymph node. The primary tumour was not
found, thus suggesting a haematologic disorder. Subsequent
biopsies of a cervical lymph node and of bone tissue from L4
revealed active sarcoidosis with no evidence of cancer. This
underlines the importance of considering all alternatives
when hypermetabolic lesions are found on 18F-FDG
PET/CT. Furthermore, 18F-FDG PET can be very useful
to indicate accessible sites for guiding fine-needle aspiration
cytology (FNAC).
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Introduction
Sarcoidosis is a systemic chronic inflammatory disease of
unknown aetiology, most commonly affecting young adults,
characterised by non-caseating epithelial granulomatous le-
sions with heterogeneous clinical manifestations affecting
multiple organs and tissues.
The respiratory system is most commonly affected, but
other organs may be involved, including eyes, skin, lymph
nodes, liver, spleen, kidneys, heart and bone marrow [1].
Isolated extrapulmonary disease is rare; in particular, ver-
tebral sarcoidosis is a very rare condition in which sclerotic
changes in the vertebrae often mimic metastatic disease [2–4].
18F-FDG PET/CT has been widely validated for the
detection of primary tumours in patients with metastatic
disease. Likewise, 18F-FDG PET/CT has also been widely
used in the diagnosis and follow-up of chronic inflammatory
disease, such as granulomatous ones [5].
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We here present the case of a 31-year-old woman with
suspected spine metastasis who underwent 18F-FDG
PET/CT to find the primary tumour.
Case Description
A 31-year-old woman with a long-lasting history of back
pain was referred to our hospital for suspected metastatic
bone lesions from an uncertain primary because of radio-
logical evidence on MRI of multiple osteolytic lesions that
were widespread on the axial skeleton.
The patient had no history of either cancer or any other
disease, but a history of possible bilateral sacroilitis, which
was later excluded by second-stage tests.
Whole-body PET/CT was performed 60 min after the
administration of 270 MBq of 18F-FDG using a 3D
PET/CT scanner (Biograph HR, Siemens AG).
18F-FDG PET/CT images showed multiple areas of
pathological FDG uptake in the spine (especially T5-
T7, T10, L1-L4), sternum, ribs, hip bone and right
femoral shaft (Fig. 1). PET images also showed
hypermetabolic activity in a left cervical lymph node
on level IV (Fig. 2).
Fig. 1 18F-
fluorodeoxyglucose PET/CT
sagittal scan (a) showing
extended spine involvement
(especially T5-T7, T10, L1-L4
vertebrae); transaxial scans (b,
c) of a 31-year-old woman
showed multiple areas of
hypermetabolic
fluorodeoxyglucose uptake in
the sternum and hip bone
Fig. 2 18F-PET PET/CT
transaxial (a), sagittal (b) and
coronal scans (c) of the same
patient showed focal FDG
uptake in a left cervical lymph
node (12×19×22 mm, see
arrows) where fine-needle
aspiration revealed a non-
caseating epithelial
granulomatous lesion
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These images were highly suggestive of widespread skel-
etal metastases, but a clear primary could not be demon-
strated, thus suggesting a possible haematologic disease.
US-guided fine-needle aspiration cytology (FNAC) of
the lymph node, shown by PET/CT, was performed and
revealed a non-caseating epithelial granulomatous lesion,
negative on Ziehl-Neelsen staining. Surgical biopsy of the
cervical lymph node and of bone tissue from L4 and L5
confirmed the diagnosis of sarcoidosis, although the patient
did not present the typical involvement of hilar lymph nodes
and pulmonary infiltration.
The patient was advised to undergo therapy with predni-
sone (25 mg/day) in order to reduce the risk of progression
in skeletal sites.
Discussion
Bone involvement in sarcoidosis is rare and can lead to the
false-positive appearance of metastatic disease on PET/CT.
In fact, accumulation of FDG at the sites of infection or
inflammation can cause false-positive results when this im-
aging technique is used in the setting of suspected or known
malignancy, as happens in inflammatory disorders such as
osteomyelitis, tuberculosis, Mycobacterium avium intracel-
lular infection and sarcoidosis [6].
When 18F-FDG PET images show hypermetabolic ac-
tivity in skeletal lesions, sarcoidosis and other inflammatory
lesions such as granulomatous processes should be consid-
ered for a differential diagnosis among lymphoproliferative
diseases and metastatic involvement from a primary tumour.
In particular, the extended bone involvement, the absence
of pulmonary uptake and the intense hypermetabolism in a
left cervical lymph node would most probably have led to
the diagnosis of a lymphoproliferative disease, but, as a
matter of fact, both sarcoidosis and lymphomas may affect
lymphoid systems and bone and appear with high metabolic
activity on 18F-FDG PET images.
The prognostic significance of bone involvement in sar-
coidosis patients, as well as a possible increased risk of
fracture at these sites, is debatable, even if it has been
associated with a chronic course of the disease; therefore,
establishing its presence is valuable in the clinical assess-
ment of these patients [7, 8]. 18F-FDG PET/CT could also
be useful to identify extrapulmonary involvement,
performing a single imaging procedure, and to guide biopsy
sampling in cases needing pathological confirmation [9].
Recently, some authors have proposed new PET tracers
to detect malignancy; these in combination with 18F-FDG
PET may be an effective method to distinguish sarcoidosis
from malignancy. Kaira et al. proposed fluorine-18-alpha-
methyltyrosine (18F-FMT), an amino acid tracer for PET, in
combination with 18F-FDG PET for the diagnosis of sar-
coidosis in patients with suspected malignancy: all patients
showed an increased uptake of 18F-FDG and no increase in
the accumulation of 18F-FMT in their lymphadenopathy
and in all extranodal lesions [10].
Only a few repor ts on 18F-FDG findings in
extrapulmonary sarcoidosis can be found in the literature
[9, 11], but, unlike other reports, our case perfectly mimicks
a lymphoma pattern because of the absence of pulmonary
involvement as well as hilar lymph nodes, although the
biopsy of the cervical lymph node clarified the diagnosis,
showing a non-caseating epithelial granulomatous lesion.
This underlines once more the importance of consid-
ering all alternatives when hypermetabolic lesions are
found on 18F-FDG PET/CT. Furthermore, 18F-FDG
PET can be very useful to indicate accessible sites for
guiding FNAC, which in many cases is indispensable
for obtaining a diagnosis.
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